News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
748,583 Results
Type
Article (52437)
Company Profile (558)
Press Release (695588)
Section
Business (217541)
Career Advice (2227)
Deals (37303)
Drug Delivery (110)
Drug Development (84785)
Employer Resources (187)
FDA (17237)
Job Trends (16181)
News (367362)
Policy (35594)
Tag
Academia (2906)
Alliances (52909)
Alzheimer's disease (1339)
Approvals (17165)
Artificial intelligence (174)
Bankruptcy (367)
Best Places to Work (12485)
Biotechnology (375)
Breast cancer (194)
Cancer (1397)
Cardiovascular disease (116)
Career advice (1857)
Cell therapy (297)
Clinical research (67424)
Collaboration (478)
Compensation (259)
COVID-19 (2720)
C-suite (118)
Data (1401)
Diabetes (172)
Diagnostics (6631)
Earnings (88950)
Employer resources (159)
Events (119920)
Executive appointments (384)
FDA (17904)
Funding (438)
Gene therapy (212)
GLP-1 (654)
Government (4758)
Healthcare (20540)
Infectious disease (2813)
Inflammatory bowel disease (117)
Interviews (355)
IPO (17118)
Job creations (4141)
Job search strategy (1581)
Layoffs (445)
Legal (8680)
Lung cancer (199)
Manufacturing (213)
Medical device (14362)
Medtech (14367)
Mergers & acquisitions (20314)
Metabolic disorders (478)
Neuroscience (1677)
NextGen Class of 2024 (7366)
Non-profit (5025)
Northern California (1687)
Obesity (273)
Opinion (200)
Patents (116)
People (60595)
Pharmaceutical (117)
Phase I (20997)
Phase II (29603)
Phase III (22098)
Pipeline (510)
Postmarket research (2816)
Preclinical (9077)
Radiopharmaceuticals (258)
Rare diseases (271)
Real estate (6464)
Regulatory (23639)
Research institute (2585)
Resumes & cover letters (383)
Southern California (1470)
Startups (3919)
United States (15704)
Vaccines (626)
Weight loss (208)
Date
Today (38)
Last 7 days (692)
Last 30 days (2582)
Last 365 days (37597)
2024 (36744)
2023 (42269)
2022 (53565)
2021 (58389)
2020 (57389)
2019 (50879)
2018 (38563)
2017 (34699)
2016 (34792)
2015 (40756)
2014 (34286)
2013 (29558)
2012 (31871)
2011 (32578)
2010 (31055)
Location
Africa (830)
Arizona (212)
Asia (41914)
Australia (6946)
California (3863)
Canada (1432)
China (306)
Colorado (176)
Connecticut (191)
Europe (93088)
Florida (528)
Georgia (140)
Illinois (418)
Indiana (231)
Maryland (668)
Massachusetts (3095)
Michigan (190)
Minnesota (311)
New Jersey (1112)
New York (1086)
North Carolina (841)
Northern California (1687)
Ohio (154)
Pennsylvania (926)
South America (1250)
Southern California (1470)
Texas (559)
Utah (111)
Washington State (417)
748,583 Results for "ht medical systems inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical WorkflowsKR-HT5 is based on Akoya’s PhenoImager® HT Platform
Akoya Biosciences, Inc., The Spatial Biology Company®, and Shanghai KR Pharmtech have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as its foundation, has received premarket approval from China’s National Medical Products Administration to support next generation pathology clinical workflows.
May 2, 2024
·
4 min read
Press Releases
Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases
December 6, 2024
·
2 min read
Press Releases
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic
August 15, 2024
·
5 min read
Drug Development
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer’s Disease Pre-Clinical Treatment with HT-ALZ
Hoth Therapeutics, Inc. (NASDAQ: HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative Alzheimer’s disease therapeutic.
March 19, 2024
·
5 min read
Press Releases
Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)
December 10, 2024
·
4 min read
Press Releases
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer’s Drug HT-ALZ
September 17, 2024
·
5 min read
Press Releases
UPDATED – Inspire Medical Systems, Inc. to Present at Jefferies London Healthcare Conference
November 15, 2024
·
1 min read
Press Releases
Inspire Medical Systems, Inc. to Present at Jefferies London Healthcare Conference
November 6, 2024
·
1 min read
Biotech Bay
Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids
Alamar Biosciences announced the commercial launch of the ARGO HT System for push-button, high sensitivity analysis of proteins in biofluids and the NULISAseq Inflammation Panel 250 for deep profiling of immune response.
January 4, 2024
·
3 min read
Biotech Beach
ASRI Announces Groundbreaking Discovery: Bifunctional 5-HT2A Antagonist and Sodium Channel Blocker Holds Promise for Bipolar Disorder Treatment
The Alexander Shulgin Research Institute has unveiled a groundbreaking discovery in the journal Molecular Pharmacology: the first bifunctional compound that acts as both a 5-HT2A receptor antagonist and a voltage-gated sodium channel blocker.
May 31, 2024
·
4 min read
1 of 74,859
Next
